

Supplementary Table 4. Factors associated with failure of first-line *H. pylori* eradication in patients who have data for clarithromycin resistance mutation status

Variable	Total	Failure	Univariable analysis		Multivariable analysis	
			OR (95% CI)	p-value	OR (95% CI)	p-value
Treatment type						
7-day tegoprazan-based triple	20	5 (25.0)	1		1	
14-day tegoprazan-based triple	21	6 (28.6)	1.200 (0.300–4.798)	0.797	0.880 (0.152–5.097)	0.886
14-day rabeprazole-based triple	5	2 (40.0)	2.000 (0.256–15.623)	0.509	0.495 (0.091–2.705)	0.417
10-day rabeprazole-based concomitant	18	5 (27.8)	1.154 (0.272–4.895)	0.846	2.254 (0.130–39.022)	0.576
10-day tegoprazan-based concomitant	27	8 (29.6)	1.263 (0.342–4.665)	0.726	0.551 (0.083–3.655)	0.537
Age						
<60 yr	32	11 (34.4)	1		1	
≥60 yr	59	15 (25.4)	0.651 (0.255–1.659)	0.368	0.284 (0.071–1.137)	0.075
Sex						
Female	40	14 (35.0)	1		1	
Male	51	12 (23.5)	0.571 (0.228–1.429)	0.232	0.911 (0.242–3.435)	0.891
BMI						
<25 kg/m ²	54	20 (37.0)	1		1	
≥25 kg/m ²	34	6 (27.6)	0.396 (0.141–1.117)	0.080	0.226 (0.055–0.935)	0.040
Smoking habit						
Never smoker	41	13 (31.7)	1			
Former smoker	27	7 (25.9)	0.754 (0.255–2.227)	0.609		
Current smoker	23	6 (26.1)	0.760 (0.243–2.376)	0.637		
Alcohol use						
Absent	52	16 (30.8)	1			
Present						
<2/week	21	5 (23.8)	0.703 (0.220–2.252)	0.553		
≥2/week	18	5 (27.8)	0.865 (0.264–2.838)	0.811		
Comorbidity						
Hypertension	41	12 (29.3)	1.064 (0.427–2.652)	0.894		
Cardiovascular disease	10	4 (40.0)	1.788 (0.460–6.942)	0.401		
Diabetes	20	5 (25.0)	0.794 (0.256–2.465)	0.689		
Dyslipidemia	14	3 (21.4)	0.640 (0.163–2.512)	0.523		
Cerebrovascular accident	6	1 (16.7)	0.480 (0.053–4.320)	0.513		
Chronic kidney disease	4	1 (25.0)	0.827 (0.082–8.331)	0.872		
Symptom						
Reflux symptom*	0	0 (0.0)	N/A	N/A		
Nausea & vomiting	0	0 (0.0)	N/A	N/A		
Gastric soreness	9	4 (44.4)	2.182 (0.537–8.871)	0.276		
Abdominal discomfort [†]	18	5 (27.8)	0.952 (0.302–3.005)	0.934		
Abdominal pain	5	3 (60.0)	4.109 (0.645–26.178)	0.135	0.797 (0.051–12.556)	0.872
Others [‡]	2	1 (50.0)	2.560 (0.154–42.525)	0.512		
Antithrombotic agents						
Aspirin	12	3 (25.0)	0.812 (0.201–3.271)	0.769		
Clopidogrel	8	5 (65.5)	4.921 (1.082–22.375)	0.039	8.528 (0.815–89.203)	0.074
Other antiplatelet agent [§]	1	1 (100.0)	N/A	>0.999		
NOAC	1	0 (0.0)	N/A	>0.999		
Other antithrombotic agent (type unknown)	2	0 (0.0)	N/A	0.999		
Indication for <i>H. pylori</i> eradication						
<i>H. pylori</i> -associated gastritis	48	15 (31.3)	1		1	
Peptic ulcer	27	10 (37.0)	1.294 (0.480–3.487)	0.610	2.537 (0.641–10.032)	0.185
EGC treated with ESD	3	0 (0.0)	N/A	0.999	N/A	0.999
Adenoma treated with ESD	13	1 (7.7)	0.183 (0.022–1.542)	0.118	0.186 (0.016–2.187)	0.181
Nodular gastritis						
	5	1 (20.0)	0.610 (0.065–5.731)	0.665		
Atrophic gastritis						
Normal (C0)	16	2 (12.5)	1		1	
Mild (C1, C2)	21	10 (47.6)	6.364 (1.149–35.229)	0.034	29.181 (1.594–534.281)	0.023
Moderate (C3, O1)	28	7 (25.0)	2.333 (0.422–12.911)	0.332	18.403 (1.339–252.912)	0.029
Severe (O2, O3)	26	7 (26.9)	2.579 (0.463–14.351)	0.279	58.700 (3.348–1029.172)	0.005
Clarithromycin resistance mutation[¶]						
Absence	60	11 (18.3)	1		1	
Presence**	31	15 (48.4)	4.176 (1.597–10.919)	0.004	9.861 (2.070–46.971)	0.004

Data are presented as n or n (%).

*Reflux symptoms include heartburn and acid regurgitation; [†]Abdominal discomfort include indigestion and bloating; [‡]Other symptoms include globus sensation, anorexia, diarrhea and belching; [§]Other antiplatelet agents include cilostazol, triflusal, and sarpogrelate; ^{||}Severity of atrophic gastritis is determined by Kimura-Takemoto classification; [¶]This indicates A2142G or A2143G mutation; **A total of 31 patients consisted of 1 A2142G and 30 A2143G.

BMI, body mass index; NOAC, non-vitamin K-dependent oral anticoagulant; EGC, early gastric cancer; ESD, endoscopic submucosal dissection; OR, odds ratio; CI, confidence interval; N/A, not applicable.